These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34052211)

  • 1. Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications.
    Mahfoud F; Weber M; Schmieder RE; Lobo MD; Blankestijn PJ; Persu A; Fischell TA; Parise H; Pathak A; Kandzari DE
    Am Heart J; 2021 Sep; 239():90-99. PubMed ID: 34052211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension.
    Mahfoud F; Renkin J; Sievert H; Bertog S; Ewen S; Böhm M; Lengelé JP; Wojakowski W; Schmieder R; van der Giet M; Parise H; Haratani N; Pathak A; Persu A
    JACC Cardiovasc Interv; 2020 Feb; 13(4):471-484. PubMed ID: 32081241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
    Kandzari DE; Weber MA; Pathak A; Zidar JP; Saxena M; David SW; Schmieder RE; Janas AJ; Langer C; Persu A; Mendelsohn FO; Ameloot K; Foster M; Fischell TA; Parise H; Mahfoud F
    Circulation; 2024 Jun; 149(24):1875-1884. PubMed ID: 38587557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design.
    Böhm M; Townsend RR; Kario K; Kandzari D; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Hickey GL; Fahy M; DeBruin V; Brar S; Pocock S
    Clin Res Cardiol; 2020 Mar; 109(3):289-302. PubMed ID: 32034481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.
    Fischell TA; Ebner A; Gallo S; Ikeno F; Minarsch L; Vega F; Haratani N; Ghazarossian VE
    JACC Cardiovasc Interv; 2016 Mar; 9(6):589-98. PubMed ID: 27013159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
    Pathak A; Rudolph UM; Saxena M; Zeller T; Müller-Ehmsen J; Lipsic E; Schmieder RE; Sievert H; Halbach M; Sharif F; Parise H; Fischell TA; Weber MA; Kandzari DE; Mahfoud F
    EuroIntervention; 2023 Sep; 19(7):602-611. PubMed ID: 37427416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.
    Kandzari DE; Townsend RR; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; Konstantinidis D; Choi J; East C; Lauder L; Cohen DL; Kobayashi T; Schmid A; Lee DP; Ma A; Weil J; Agdirlioglu T; Schlaich MP; Shetty S; Devireddy CM; Lea J; Aoki J; Sharp ASP; Anderson R; Fahy M; DeBruin V; Brar S; Böhm M;
    J Am Coll Cardiol; 2023 Nov; 82(19):1809-1823. PubMed ID: 37914510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA; Mahfoud F; Schmieder RE; Kandzari DE; Tsioufis KP; Townsend RR; Kario K; Böhm M; Sharp ASP; Davies JE; Osborn JW; Fink GD; Euler DE; Cohen DL; Schlaich MP; Esler MD
    JACC Cardiovasc Interv; 2019 Jun; 12(12):1095-1105. PubMed ID: 31221299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies.
    Fengler K; Rommel KP; Lapusca R; Blazek S; Besler C; Hartung P; von Roeder M; Kresoja KP; Desch S; Thiele H; Lurz P
    Hypertension; 2019 Aug; 74(2):341-348. PubMed ID: 31203726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Lobo MD; Sharp ASP; Bloch MJ; Basile J; Wang Y; Saxena M; Lurz P; Rader F; Sayer J; Fisher NDL; Fouassier D; Barman NC; Reeve-Stoffer H; McClure C; Kirtane AJ;
    Circulation; 2019 May; 139(22):2542-2553. PubMed ID: 30880441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.
    Azizi M; Daemen J; Lobo MD; Mahfoud F; Sharp ASP; Schmieder RE; Wang Y; Saxena M; Lurz P; Sayer J; Bloch MJ; Basile J; Weber MA; Rump LC; Levy T; Sapoval M; Sanghvi K; Rader F; Fisher NDL; Gosse P; Abraham J; Claude L; Barman NC; McClure CK; Liu Y; Kirtane AJ;
    JACC Cardiovasc Interv; 2020 Dec; 13(24):2922-2933. PubMed ID: 33357531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ReferencesEfficiency and safety of renal denervation via cryoablation (Cryo-RDN) in Chinese patients with uncontrolled hypertension: study protocol for a randomized controlled trial.
    Chen H; Ji M; Zhang Y; Xu Y; Qiao L; Shen L; Ge J
    Trials; 2019 Nov; 20(1):653. PubMed ID: 31779672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.
    Böhm M; Mahfoud F; Townsend RR; Kandzari DE; Pocock S; Ukena C; Weber MA; Hoshide S; Patel M; Tyson CC; Weil J; Agdirlioglu T; Fahy M; Kario K
    Eur Heart J; 2019 Mar; 40(9):743-751. PubMed ID: 30608521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension.
    Sesa-Ashton G; Nolde JM; Muente I; Carnagarin R; Lee R; Macefield VG; Dawood T; Sata Y; Lambert EA; Lambert GW; Walton A; Kiuchi MG; Esler MD; Schlaich MP
    Hypertension; 2023 Apr; 80(4):811-819. PubMed ID: 36762561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of catheter-based sham renal denervation in hypertension: systematic review and meta-analysis.
    Fernandes A; David C; Pinto FJ; Costa J; Ferreira JJ; Caldeira D
    BMC Cardiovasc Disord; 2023 May; 23(1):249. PubMed ID: 37173636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension.
    Wang TD; Lee YH; Chang SS; Tung YC; Yeh CF; Lin YH; Pan CT; Hsu CY; Huang CY; Wu CK; Sung PH; Chiang LT; Wang YC; Tsai WC; Lin TT; Lin CP; Chen WJ; Hwang JJ
    Acta Cardiol Sin; 2019 May; 35(3):199-230. PubMed ID: 31249454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.
    Mathiassen ON; Vase H; Bech JN; Christensen KL; Buus NH; Schroeder AP; Lederballe O; Rickers H; Kampmann U; Poulsen PL; Hansen KW; Btker HE; Peters CD; Engholm M; Bertelsen JB; Lassen JF; Langfeldt S; Andersen G; Pedersen EB; Kaltoft A
    J Hypertens; 2016 Aug; 34(8):1639-47. PubMed ID: 27228432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.